Advertisement
Advertisement

CPIX

CPIX logo

Cumberland Pharmaceuticals Inc

7.80
USD
Sponsored
+0.12
+1.56%
Aug 07, 15:59 UTC -4
Closed
exchange

After-Market

7.73

-0.07
-0.90%

Cumberland Pharmaceuticals Inc Profile

About

Cumberland Pharmaceuticals, Inc., headquartered in Nashville, Tennessee, is a specialty pharmaceutical company focused on acquiring, developing, and commercializing branded prescription products for the acute care and gastroenterology markets. The company's lead product candidate, Amelior, which is in phase III clinical trials, is an intravenous formulation of ibuprofen for the treatment of both pain and fever. Its products also comprise Acetadote, an intravenous formulation of N-acetylcysteine for the treatment of acetaminophen poisoning; and Kristalose, a prescription laxative product, which is a crystalline form of lactulose to enhance patient acceptance and compliance. In addition, the company is developing a treatment for fluid buildup in the lungs of cancer patients and an anti-infective for treating fungal infections in immuno-compromised patients.

Info & Links

CEO

A. J. Kazimi

Headquarters

1600 WEST END AVENUE, SUITE 1300
NASHVILLE, TN 37203, UNITED STATES

Industry

Medical Drugs

Sector

Medical

Website

www.cumberlandpharma.com

Auditor

Carr, Riggs & Ingram, LLC

Share holders

87

Employees

93

Cumberland Pharmaceuticals Inc Statistics

Valuation Measures

Market Capitalization2

115.82M

Enterprise Value

110.05M

Enterprise Value/EBITDA(ttm)

-38.98

Price to Earnings Ratio(ttm)

--

Price to Sales(ttm)

3.74

Price to Book(mrq)

5.48

Price to Cash(ytd)

21.27

Profitability

Gross Margin(ttm)

82.99%

Operating Margin(ttm)

-20.44%

Profit Margin(ttm)

-19.15%

Return on Equity(ttm)

-26.77%

Return on Invested Capital(ttm)

-25.69%

Return on Assets(ttm)

-8.97%

Income Statement

Revenue(ttm)

41.94M

Revenue Per Share(ttm)

2.80

Gross Profit(ttm)

34.76M

EBITDA(ttm)3

-2.82M

Net Income Available to Common(ttm)

-7.38M

Diluted EPS(ttm)

-0.71

Share Statistics

Beta (5Y Monthly)

0.08

52-Week Change

137.80%

S&P 500 52-Week Change

21.72%

S&P 500 Member

No

Stock Optionable

Yes

Total Shares Outstanding1

14.98M

Dividend Yield

0.00%

Float4

8.68M

% Held by Insiders

42.07%

% Held by Institutions

15.51%

Balance Sheet

Total Cash(mrq)

11.01M

Total Cash Per Share(mrq)

0.73

Total Debt(mrq)

5.24M

Total Debt/Equity(mrq)

24.60%

Current Ratio(mrq)

0.95%

Quick Ratio(mrq)

0.79%

Book Value Per Share(mrq)

1.42

Cash Flow

Operating Cash Flow Per Share(ytd)

0.03

Free Cash Flow(ytd)

387.00K

Table Key

mrq = Most Recent Quarter

ttm = Trailing Twelve Months

ytd = Year To Date

Footnotes

Data provided by Zacks Investment Research or calculated by FXEmpire. All numbers are rounded to the closest decimal.

  • 1 Total Shares outstanding is taken from the most recently filed quarterly or annual report.
  • 2 Market Cap is calculated using total shares outstanding and the most recent share price.
  • 3 EBITDA is calculated using methodology that may differ from that used by a company in its reporting.
  • 4 The float is a measure of the number of shares available for trading by the public. It's calculated by taking the number of issued and outstanding shares minus any restricted stock, which might not be publicly traded.
Advertisement